You are here: Industry Insights > Market News > M&As this week: Eurofins Scientific, Baxter International

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

TAYACN Drying Ammonium thiocyanate ZLG series vibration fluidized bed dryer

TAYACN Drying Nickel chloride water ZLG series vibration fluidized bed dryer

TAYACN Drying Flavoring ZLG series vibration fluidized bed dryer

TAYACN Drying Resin ZLG series vibration fluidized bed dryer

TAYACN Drying Thiourea particles ZLG series vibration fluidized bed dryer

TAYACN Drying Sodium percarbonate ZLG series vibration fluidized bed dryer

M&As this week: Eurofins Scientific, Baxter International

pharmaceutical-technologyAugust 07, 2017

Tag: M&As , Eurofins Scientific , Baxter International

Favorites

Luxembourg-based life sciences company Eurofins Scientific plans to acquire DiscoverX, a reagents provider based in the US.

The acquisition will strengthen Eurofins Scientific’s drug discovery services.

"Baxter International has announced the acquisition of Claris Injectables for approximately $625m."

Baxter International has announced the acquisition of Claris Injectables for approximately $625m.

Baxter is a medical products company based in the US, while Claris is an injectables pharmaceutical company based in India.

The acquisition will provide Baxter with access to Claris’ product portfolio and pipeline and strengthen its position in the generic injectable medicines market.

Previous:Deals this week: Innoviva, Seattle Genetics, PlasmaGen BioSciences

Next:Biopharma stages a strong recovery over the first half even as M&A deals disappoint

Alzheimer’s Disease: Charting the Course from Plaques to Promise

Muhammad Farhan KhalidMay 28, 2025

New Tools，New Hope，New Frontier

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

PharmaSourcesMay 16, 2025

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

PR NewswireMay 12, 2025

M&As this week: Eurofins Scientific, Baxter International | Pharmasources.com

Illuccix China Phase 3 Study Completes Enrolment

PR NewswireMay 13, 2025

Telix Pharmaceuticals Limited announces that the pivotal Phase 3 registration study of TLX591-CDx for prostate cancer imaging in Chinese patients has completed patient enrolment.